Navigation Links
Daiichi Sankyo And Coherus BioSciences Establish Strategic Collaboration To Develop And Commercialize Biosimilar Candidates
Date:5/7/2012

REDWOOD CITY, Calif. and TOKYO, May 7, 2012 /PRNewswire/ -- Coherus BioSciences, Inc (hereafter, Coherus BioSciences) and Daiichi Sankyo, Co. Ltd. (hereafter, Daiichi Sankyo; TSE 4568) announced today the execution of an exclusive agreement to develop and commercialize biosimilar forms of etanercept and rituximab in certain Asian countries including Japan.

(Logo: http://photos.prnewswire.com/prnh/20120507/SF01448LOGO)

Under the terms of the agreement, Daiichi Sankyo and Coherus BioSciences will work together to develop, manufacture and commercialize  biosimilar forms of etanercept and rituximab developed by Coherus BioSciences. Upon marketing approval, Daiichi Sankyo will commercialize these products in Japan, South Korea and Taiwan. Coherus has retained all additional development and commercial rights outside of the licensed territories.  Specific financial terms of the agreement were not disclosed.

"This collaboration to develop and commercialize these biosimilar candidates with a leading global healthcare company such as Daiichi Sankyo is a significant strategic event for Coherus BioSciences and validates our unique business model strategy," said Denny Lanfear, Chief Executive Officer.  "This agreement demonstrates that our strategy and model position us well to make a major impact toward providing access to biosimilar therapies for patients on a global basis."

"Coherus BioSciences has established an outstanding business model, a very experienced biologic development team and outstanding capabilities," said Joji Nakayama, President & CEO of Daiichi Sankyo. "By creating an opportunity for an early entry into the biosimilars market, this agreement will strengthen our internal platform for manufacturing and developing biopharmaceuticals, leading directly to the introduction of other biosimilars therapies in the future."

Sagent Advisors
'/>"/>

SOURCE Coherus BioSciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
2. Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs
3. DAIICHI SANKYO EUROPE GmbH Selects DATATRAK eClinicalâ„¢ for Pan-European Systolic Hypertension Study
4. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
5. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
6. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
7. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
8. Milestone Biosciences, LLC Further Strengthens Executive Management Team
9. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
10. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
11. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 2015 Regis Technologies announced new ... oncology drug substances. , Regis Technologies is proud to ... Potent Compound Suite (PCS) for 2015. , Regis is ... cGMP facility in Morton Grove, Illinois. The PCS addition ... compounds up to about one kilogram per batch. ...
(Date:2/26/2015)... -- Epic Sciences announced today that President and CEO ... Annual Cowen and Company Health Care Conference on Wednesday, March ... Floor. The conference will be held at the Boston ... is developing diagnostic tests of high clinical utility to ... occur during the course of cancer treatments. From a ...
(Date:2/26/2015)... , Feb. 26, 2015 CytomX, a ... cancer, today announced that Sean McCarthy , D. ... at the upcoming Cowen and Company 35 th ... . Dr. McCarthy,s presentation will take place at 4 ... CytomX Therapeutics CytomX Therapeutics develops Probody™ therapeutics for ...
(Date:2/26/2015)... LONDON , February 26, 2015 ... of subjects into PEACH, the first pivotal trial ... dialysis dependent chronic kidney disease (DD-CKD), has completed ... achieved. PT20, invented by leading UK-based ... licensed by Phosphate Therapeutics, is a novel phosphate ...
Breaking Biology Technology:Regis Extends cGMP Services to Oncology Market 2Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference 2Phosphate Therapeutics Announces Completion of Subject Recruitment Into the PEACH Pivotal Phase 2 Study of its Novel Phosphate Binder (PT20) for the Treatment of Hyperphosphataemia 2Phosphate Therapeutics Announces Completion of Subject Recruitment Into the PEACH Pivotal Phase 2 Study of its Novel Phosphate Binder (PT20) for the Treatment of Hyperphosphataemia 3
... physicists have successfully landed a one-two punch on a ... then dosing its perimeter with a laser beam, to ... standstill. The findings, published in Nature Physics ... special quantum properties and in precision-measurements for nanotechnology. The ...
... N.C., June 17 Pharmaceutical Institute (PI), a leading provider ... today announced the release of a new e-course titled, ... newest addition to the company,s Managed Markets Excellence(TM) ... e-course provides a comprehensive overview of the challenges confronting the ...
... (NYSE: DGX ), the world,s leading provider of ... for its previously announced cash tender offer to purchase up ... of its 5.125% Senior Notes due 2010 and 7.50% Senior ... conditions of the tender offer are described in the Offer ...
Cached Biology Technology:Pharmaceutical Institute Launches New E-Course Focused on Health Policy 2Pharmaceutical Institute Launches New E-Course Focused on Health Policy 3Quest Diagnostics Announces Final Tender Offer Results 2Quest Diagnostics Announces Final Tender Offer Results 3
(Date:2/24/2015)... , Feb. 24, 2015 This report analyzes the ... the following Segments: Face Biometrics, and Voice Biometrics. The report provides ... Japan , Europe , ... Africa , and Latin America ... through 2020. Also, a seven-year historic analysis is provided for these ...
(Date:2/19/2015)... , Feb .19, 2015 Research and ... the addition of the "Military Electro-Optical / ... Sensor Technology, by Platform - Forecast to 2020" ... The military electro-optical/infrared systems market is expected to ... CAGR of 7.71%. This report segments ...
(Date:2/12/2015)... Minn. , Feb. 12, 2015   ... company specializing in clinical study management systems, has ... Program , further distinguishing iMedNet ... Clinical Research Organizations (CROs) and healthcare consultants.  Building ... support, prospective customer referrals and numerous co-marketing opportunities), ...
Breaking Biology News(10 mins):World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... tumors often fail to respond to promising new medication. ... tumor marker for the development of this resistance. A ... great the chances of success are for chemotherapy. At ... promising brain tumor therapy. Dr. Wolf Mller, senior ...
... first information about how fat causes hypertension have been identified ... identify which obese people and maybe some thin ones ... would work best for them. Medical College of ... PTP1B puts mice at risk for hypertension by interfering with ...
... introduced to the U.S. from Europe and other places, garlic ... new study indicates that eventually, however, its primary weapon ... potent. The study, in Proceedings of the National ... show that evolutionary forces can alter the very attributes that ...
Cached Biology News:Why don't brain tumors respond to medication? 2New information about how fat increases blood pressure could help identify those at risk 2New information about how fat increases blood pressure could help identify those at risk 3Over time, an invasive plant loses its toxic edge 2Over time, an invasive plant loses its toxic edge 3
... APO-BRDU Kit is a two color staining ... cellular DNA to detect apoptotic cells by ... and reagents required for measuring apoptosis in ... for assessing reagent performance; washing, reaction and ...
... The CHEMICON APO-BRDU Kit is ... labeling DNA breaks and total cellular DNA ... The kit contains the instructions and ... including; positive and negative control cells for ...
... PowerPac HV high-voltage power supply, with temperature probe, ... of 5,000 V, 500 mA, and 400 W. ... temperature between 0 and 90 degrees C during ... transfer. Power cord and instructions are provided. Dimensions ...
The Trans-Blot Plus gel and cassette assembly tray is used to hold the Trans-Blot Plus gel holder cassette, buffer, and other materials for the gel and membrane sandwich during their assembly....
Biology Products: